Latest Biotech News

Fulcrum’s stock plunged after it announced it was discontinuing its sole clinical-stage sickle cell candidate pociredir and pursuing strategic alternatives, following a regulatory finding that...

The European Union is poised to reshape how emerging genomic techniques (NGTs) are overseen, as regulators move toward a new framework with direct implications for food sustainability goals. The...

Abivax reported positive Phase 3 maintenance efficacy for obefazimod in ulcerative colitis, but said a small number of malignancies in the higher-dose cohort triggered major market fallout. In...

Travere Therapeutics expanded its rare kidney disease pipeline in a deal with Everest Medicines, licensing civorebrutinib for development and commercialization outside China and parts of East and...

NanoMosaic and Solid Biosciences announced a comarketing agreement aimed at improving AAV gene-therapy delivery development and manufacturing analytics. Under the collaboration, NanoMosaic will...

The FDA issued additional draft guidance describing how cell and gene therapy developers can use prior knowledge—covering clinical, nonclinical, and manufacturing contexts—to support future...

ASCO 2026 showcased early-stage cancer signals across multiple non-overlapping targets, including WEE1 inhibition and precision stratification approaches intended to refine which patients...

Longevity startup NewLimit raised $435 million in a Series C round ahead of planned first-in-human testing for its lead liver reprogramming approach. Founders Fund led the financing, joined by...

Fulcrum Therapeutics scrapped its lead sickle cell disease program, pociredir, and launched a comprehensive strategic review after FDA raised heightened concerns about malignancy risk tied to PRC2...

The Allen Institute is launching a $200 million effort, the Brain Health Accelerator, aimed at translating brain atlas-scale understanding into medicines for neurodegenerative diseases. The...

NanoMosaic and Solid Biosciences moved to co-market and technically align their gene therapy workflow tools, targeting AAV vector development and manufacturing analytics. The deal pairs...

A portable bedside PET scanner technology was presented as a new option for real-time imaging during interventional procedures. Researchers at Washington University in St. Louis described a...

A new licensing push highlighted Lilly’s continued expansion in GLP biology with a $75 million upfront deal for Hanmi’s long-acting GLP-2 analog sonefpeglutide. Lilly secured exclusive worldwide...

Abivax’s Phase 3 ulcerative colitis maintenance readout showed strong efficacy, but the stock moved sharply lower after malignancy cases emerged among treatment recipients. In the Abtect trial,...

The FDA approved Foundation Medicine’s FoundationOne CDx assay as a companion diagnostic to identify patients for Pfizer’s Talzenna plus Xtandi regimen in HRR-mutated metastatic...

Anti-aging startup NewLimit raised $435 million at a valuation above $3 billion in a Series C financing led by Founders Fund. The company said it expects to start human testing next year for its...

The FDA released additional CBER draft guidance detailing how cell and gene therapy developers can leverage prior knowledge. The agency outlined the types of information companies may reuse across...

Evosep and Molecular You announced a partnership intended to standardize high-throughput multiomic biomarker testing workflows. The collaboration integrates Evosep’s Eno liquid chromatography...

NanoMosaic and Solid Biosciences announced a comarketing agreement focused on improving AAV manufacturing analytics for gene therapy developers. NanoMosaic will promote its Tessie automated plate...

Servier will acquire Edgewise Therapeutics’ muscular dystrophy business in a deal valued at up to $2.65 billion, including $1.55 billion upfront and as much as $1.1 billion tied to regulatory and...